Table 1.

Patient demographics and indinavir PK parameters

PatientDose/BSA (mg q8h/m2)Age (yr)SexaWt (kg)Ht (cm)BSA (m2)BMICDCbclassificationBaselineIndinavir PK parameters
No. of CD4+ cells/μl%CD4Viral load (log no. of copies/ml)Cmax(mg/liter)Tmaxc(h)Cmin (mg/liter)AUC (mg × h/liter)CL/Fd(liters/h)t1/2e (h)
15569.6M31.01371.0817C260221.54.188.31.50.05125.223.80.84
244110.0M47.51451.3623B266927.03.0814.11.50.05030.719.60.87
355011.6M30.01421.0915C3602.83.8711.51.00.04645.313.30.56
445510.0M46.21441.3222C254721.33.9612.71.00.05626.023.10.87
545510.2F22.11280.8814C3100.93.9716.62.00.09555.17.30.66
652211.6M33.91411.1517C247026.92.467.12.00.07325.024.10.65
74659.0F21.71230.8614B247229.04.9228.82.00.800117.03.40.90
852211.0F33.01451.1516C230015.03.8814.82.00.13049.012.30.68
948813.6M56.01711.6419B3251.44.237.32.00.07119.142.00.89
1049612.1M36.41451.2117A236518.03.7411.02.00.09541.614.40.71
1153312.1F47.21671.5017A233628.04.433.24.00.11315.950.30.83
Mean49811.036.81441.201735117.43.8812.31.90.14440.921.20.77
SD411.411.1140.24323311.00.666.70.80.21928.314.10.12
%CVf 812301020176663175542153696715
  • a M, male; F, female.

  • b CDC, Centers for Disease Control and Prevention.

  • c Tmax, time toC max.

  • d CL/F, clearance/bioavailability.

  • e t1/2, elimination rate constant.

  • f %CV, Percent coefficient of variation.